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a  b  s  t  r  a  c  t
Z-Vallesiachotamine  is a monoterpene  indole  alkaloid  that  has  a -N-acrylate  group  in  its  structure.
This  class of compounds  has  already  been  described  in different  Psychotria  species.  Our  research  group
observed  that  E/Z-vallesiachotamine  exhibits  a multifunctional  feature,  being  able  to  inhibit  targets
related  to  neurodegeneration,  such  as  monoamine  oxidase  A, sirtuins  1  and  2, and butyrylcholinesterase
enzymes.  Aiming  at  better  characterizing  the multifunctional  proﬁle  of  this  compound,  its  effect  on
cathecol-O-methyltransferase  activity  was  investigated.  The  cathecol-O-methyltransferase  activity  was
evaluated in  vitro  by  a ﬂuorescence-based  method,  using  S-(5′-adenosyl)-l-methionine  as  methyl  donor
and aesculetin  as substrate.  The  assay  optimization  was  performed  varying  the  concentrations  of  methyl
donor  (S-(5′-adenosyl)-l-methionine)  and  enzyme.  It was observed  that  the  highest  concentrations  of
both  factors  (2.25  U of  the  enzyme  and 100  M of  S-(5′-adenosyl)-l-methionine)  afforded  the more
reproducible  results.  The  in vitro  assay  demonstrated  that Z-vallesiachotamine  was  able  to inhibit  the
cathecol-O-methyltransferase  activity  with  an IC close  to 200  M.  Molecular  docking  studies  indi-50
cated  that  Z-vallesiachotamine  can  bind  the catechol  pocket  of catechol-O-methyltransferase  enzyme.
The present  work  demonstrated  for  the  ﬁrst time  the  inhibitory  properties  of  Z-vallesiachotamine
on  cathecol-O-methyltransferase  enzyme,  affording  additional  evidence  regarding  its  multifunctional
effects  in  targets  related  to neurodegenerative  diseases.
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Z-Vallesiachotamine (1) is a monoterpene indole alkaloid (MIA)
rstly described for Vallesia glabra (Cav.) Link (= V. dichotoma Ruiz
t Pav), Apocynaceae (Djerassi et al., 1966). It has a -N-acrylate
roup, which confers a characteristic UV proﬁle, with a high
olar attenuation coefﬁcient (ε) at 290 nm region. Therefore,
allesiachotamine-like alkaloids can be easily detected in alka-
oid fractions by LC-DAD, based also on previous knowledge of
he species or genus. This MIA  had already been isolated from
everal different families, including Apocynaceae (Evans et al.,
968; Cheng et al., 2014), Loganiaceae (Zhong et al., 2014), and
ubiaceae (Heitzman et al., 2005). Speciﬁcally in Rubiaceae family,
his alkaloid had already been described for several species of
alicoureeae Robbr. & Manen (Psychotrieae Cham. & Schltdl. s. lat.)
∗ Corresponding author.
E-mail: amelia.henriques@ufrgs.br (A.T. Henriques).
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http://dx.doi.org/10.1016/j.bjp.2015.07.002
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
tribe (Klein-Júnior et al., 2014), including Psychotria dichroa
(Standl.) C.M. Taylor (=Cephaelis dichroa (Standl.) Standl.) (Solis
et al., 1993), Psychotria bahiensis DC (Paul et al., 2003), Psychotria
cuspidata Bredem. ex Schult. (=Palicourea acuminata (Benth.)
Borhidi) (Berger et al., 2012), Palicourea rigida Kunth (Soares et al.,
2012) and more recently, for Psychotria suterella Müll.Arg. and
Psychotria laciniata Vell. (Passos et al., 2013a).
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The pharmacological potential of vallesiachotamine was
also reported. Shang et al. (2010) evaluated the in vitro
 Ltda. All rights reserved.
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% inhibition = 100 − test × 100
NCC. dos Santos Passos et al. / Revista Bras
nti-inﬂammatory activity of several alkaloids, however no signif-
cant effect was observed for vallesiachotamine, which displayed
nly 41.9% of cyclooxygenase-2 inhibition at 100 M.  The cyto-
oxicity in human melanoma cells was analyzed by MTT  assay,
iving an IC50 value of 14.7 M.  By ﬂow cytometry analysis, it
as observed that this MIA  induced G0/G1 arrest, increasing the
ub-G1 hypodiploid cells number. The authors concluded that the
ytotoxicity observed for this compound is mainly due to apopto-
is and necrosis processes (Soares et al., 2012). In addition to the
eported activities, different central effects were also described for
-vallesiachotamine, including butyrylcholinesterase (BChE) and
onoamine oxidase-A (MAO-A) inhibitory activity (Passos et al.,
013b) and sirtuins (SIRT1 and SIRT2) modulation (Sacconnay et al.,
015).
Another important target related to neurodegenerative dis-
rders is the cathecol-O-methyltransferase (COMT) enzyme
Mannisto and Kaakkola, 1999). COMT is a methyltransferase
-adenosylmethionine-dependent responsible for catalyzing the
ethylation of catecholamines, such as dopamine, leading to their
nactivation. Two isoforms are described: a soluble (S-COMT) and
 membrane bounded (MB-COMT). S-COMT and MB-COMT can
e differentiated by their afﬁnity for substrates and their tissue
istribution. The MB-COMT has a high afﬁnity for catecholamine
eurotransmitters, being found in neurons and glial cells of rat
rains (Shirakawa et al., 2004). However, little is known regarding
he regional distribution and cellular localization of COMT in the
uman brain. Kastner et al. (2006) found imunoreactivity for COMT
nto neurons and glial cells in the striatum in postmortem stud-
es of human brains. Additionally, the presence of COMT mRNA
as demonstrated in neurons of striatum and prefrontal cortex
Matsumoto et al., 2003).
COMT is the major enzyme responsible for dopamine degra-
ation in the prefrontal cortex. In the striatum, in addition to
OMT, MAO-B enzyme and the dopamine transporter (DAT) are
nvolved in the inactivation of this neurotransmitter (Rybakowski
t al., 2006). The role of COMT in the dopaminergic transmission
akes this enzyme an interesting target for the discovery of new
ubstances for the treatment of diseases such as schizophrenia,
bsessive-compulsive disorder, bipolar disorder, anxiety, and panic
isorder (Brisch et al., 2009). Furthermore, the COMT inhibitor
ntacapone is clinically used in association with levodopa in the
reatment of Parkinson’s disease (PD) (Hamaue et al., 2010).
Taking into account the already described BChE, MAO-A, and
irtuin inhibitory effects described for vallesiachotamine alkaloids,
he present study aimed at developing and implementing a proto-
ol for the evaluation of COMT activity suitable for the screening
f plant extracts and isolated natural products. Further, we  used
he optimized protocol to evaluate the potential effects of vallesia-
hotamine on COMT activity, and an in silico approach to elucidate
he molecular mechanisms involved in the interactions between
allesiachotamine and COMT.
aterials and methods
hemicals
Potassium phosphate monobasic, potassium phosphate diba-
ic, l-cysteine, magnesium chloride hexahydrate, esculetin,
copoletin, DMSO, S-(5′-adenosyl)-l-methionine iodide (SAM), 3,5-
initrocatechol (DNC), and porcine COMT were purchased from
igma Chemical Co. (St. Louis, MO,  USA). Z-Vallesiachotamine was
solated from Psychotria laciniata Vell. collected from the Atlantic
orest of Cocal do Sul (Santa Catarina, Brazil S26◦80’; W48◦95’;
CN 182552, Herbarium of the Federal University of Rio Grande
o Sul), according to previously described (Passos et al., 2013b).de Farmacognosia 25 (2015) 382–386 383
Brieﬂy, the dried leaves were extracted with EtOH at room tem-
perature. The solvent was  removed under vacuum and the residual
extract dissolved in 1 N HCl and exhaustively extracted with CH2Cl2
in order to remove non-polar constituents. Subsequently, the acid
extracts were alkalinized with 25% NH4OH (pH 9–10) and parti-
tioned with CH2Cl2, resulting in the P. laciniata alkaloid-enriched
extract. This extract was  fractionated by reversed-phase medium
pressure chromatography (RP-MPLC) with a H2O-CH3CN gradient
step. Fraction containing Z-vallesiachotamine was submitted to
preparative HPLC with isocratic elution (H2O:CH3CN, 40:60, v/v),
rate 5 ml/min, and detection at 280 nm,  affording the isolated com-
pound (purity > 95%).
COMT enzymatic assay optimization
The COMT inhibitory activity was  assessed based on methods
previously described in the literature (Kurkela et al., 2004; Yalcin
and Bayraktar, 2010), using aesculetin as COMT substrate and SAM
as the methyl donor. The O-methylation of aesculetin catalyzed by
COMT to afford scopoletin was  monitored by ﬂuorescence mea-
surements (ex = 355 nm and em = 460 nm). The general reaction
is presented below:
ES + SAMCOMT−→ SAH + Scopoletin
where ES is aesculetin, SAM is the methyl donor S-(5′-adenosyl)-
l-methionine iodide, COMT is catechol-O-methyltransferase, and
SAH is S-adenosyl-homocystein.
For setting up the experimental conditions, different concen-
trations of the porcine COMT and of the methyl donor substrate,
SAM, were tested. COMT was  evaluated in concentrations of 0.75,
1.50 and 2.25 U/well while SAM was  tested in concentrations of
20, 60, and 100 M.  The concentration of the catechol substrate
aesculetin was  kept constant at 0.6 M.  The control for COMT inhi-
bition, DNC, was  tested in concentration corresponding to its IC50
(35 nM)  (Kurkela et al., 2004). Calibration curves of aesculetin and
scopoletin (0.1–2 M)  were constructed in triplicate in order to cal-
culate the rates of the O-methylation of aesculetin into scopoletin.
Evaluation of vallesiachotamine in COMT enzymatic assay
For the assay, 190 l potassium buffer (pH 7.4) containing
20 mM l-cysteine, 5 mM magnesium chloride, 15 l of 100 M aes-
culetin (ﬁnal concentration 6 M),  15 l of 150 U/ml porcine COMT
(ﬁnal concentration 2.25 U/well), and 5 l of sample (ﬁnal concen-
tration varying from 15.62 to 500 M)  solubilized in 100% DMSO
were used. In the blank wells, the enzyme was  replaced by the
corresponding amount of buffer. The plates were preincubated
for 5 min  at 37 ◦C, followed by the addition of 25 l of 100 mM
SAM (ﬁnal concentration 100 M).  For the controls, samples were
replaced by the corresponding amount of DNC solution (ﬁnal
concentration corresponding to the IC50 value, 35 nM) or DMSO.
Readings were performed at temperature of 37 ◦C, for 60 min,
in 4 min  intervals. A microplate reader (SpectraMax® Molecular
Devices, CA, USA) was used for ﬂuorescence measurements. The
excitation and emission wavelengths were adjusted to 355 and
460 nm,  respectively. Calculations were performed using Excel and
were based on the following equation:where test is the difference between the test ﬂuorescence reading
in time 60 and 0 min; and NC is the difference between the nega-
tive control (DMSO) ﬂuorescence readings in time 60 and 0 min.
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olecular modeling
The crystallographic structure of human soluble COMT (human
-COMT) (PDB ID: 3BWM) (Rutherford et al., 2008) was retrieved
rom the protein data bank (http://www.wwpdb.org/). Protein was
repared for structural inspection and docking using MOE  2014.09.
he crystallized water molecules and the co-crystallized ligand
NC were removed, and the missing hydrogen atoms were added.
he molecular docking protocol was developed using GOLD, version
.2 (CCDC). COMT pocket was centered in the space occupied by the
o-crystallized ligand DNC and delimited by an 8 A˚ radius. For each
igand, 100 docking solutions were generated by using 100,000
OLD Genetic Algorithm interactions (Preset option). Docking
oses were evaluated and ranked according to the ChemPLP sco-
ing function. Docking protocol was validated by re-docking the
o-crystallized ligand DNC in the COMT active site. RMSD values
etween the best ranked docking solution and the co-crystallized
igand lower than 2.0 A˚ were accepted as satisfactory.
esults and discussion
One of the aims of this study was to optimize the parame-
ers for the evaluation of alkaloid fractions and MIAs on COMT.
his enzyme is responsible for the methylation of dopamine and
ther endogenous and xenobiotic catechol substrates. Therefore,
ts inhibition can increase dopamine levels and lead to an improve-
ent of the motor symptoms associated with PD (Dickinson and
lvevág, 2009). In fact, COMT inhibitors have been used clinically
or some years in combination with levodopa. The ﬁrst generation
f these inhibitors, as tropolone, demonstrated low in vivo efﬁcacy
ith high toxic effects. The second generation, represented by tol-
apone and entacapone, replaced ﬁrst generation COMT inhibitors,
owever they still have several dopaminergic and gastrointestinal
ide-effects. Nowadays, opicapone is under clinical trials, starting
he third generation of this class, with higher potency and lower
oxicity (Jatana et al., 2013; Bonifácio et al., 2014).
Different methods have already been reported for the in vitro
valuation of COMT inhibition, including spectrophotometric, ﬂuo-
imetric and radioactive methods. Most of these methods describe
he quantiﬁcation of the product and of the remaining substrate
y using chromatographic techniques; however, they are not well
pplicable for screening assays. Yalcin and Bayraktar (2010) devel-
ped a ﬂuorescence-based method for the COMT evaluation, using
esculetin as the catechol substrate which is methylated to afford
he ﬂuorescent product scopoletin.
Aiming at optimizing a screening method based on Yalcin and
ayraktar (2010) study, the linearity of both esculetin and scopo-
etin were checked in ﬁve different concentrations, by triplicate
xperiments. It was possible to observe that both compounds
emonstrated a linear behavior in the concentrations evaluated,
ith coefﬁcient of determination higher than 0.99, which is in
ccordance to the literature for enzymatic assays (Tiwari and
iwari, 2010).
The activity of COMT was evaluated using the enzyme obtained
rom porcine liver. Incubation temperature (37 ◦C), incubation time
60 min) and substrate concentration (0.6 M)  were kept constant
n all experiments. The parameters evaluated were the concen-
ration of the methyl donor substrate (SAM) and the amount of
nzyme in the incubation medium. The combined variation of these
arameters allows us to observe that higher concentrations of the
nzyme and of the donor led to more reproducible results. With
.75 U of the enzyme, and 20 M of the substrate (lowest levels),
he relative standard deviation (RSD) was 59.9%, while with 2.25 U
f the enzyme and 100 M of SAM (highest levels), the RSD was just
.6%, which is in accordance to bioanalytical methods validationde Farmacognosia 25 (2015) 382–386
(Tiwari and Tiwari, 2010). Taking this into account, both enzyme
and methyl donor higher levels were chosen to evaluate vallesia-
chotamine effect.
Yalcin and Bayraktar (2010) evaluated phenolic and alkaloids
enriched extracts obtained from Cistus parviﬂorus Lam., Vitex agnus-
castus L. and Peganum harmala L. The authors observed that an
alkaloid fraction from P. harmala demonstrated better inhibi-
tion results than the phenolic extracts, with an IC50 value of
1.09 g/ml. Taking into account that harmaline and harmalol were
the main compounds detected for P. harmala, the effect of both
-carboline (C) alkaloids were also evaluated, exhibiting IC50 val-
ues of 0.98 and 3.59 M,  respectively. Kinetic experiments revealed
that harmaline showed a mixed-type COMT inhibition regarding
the methyl donor substrate SAM while harmalol displayed an
uncompetitive mode of inhibition.
In the present study, the COMT inhibitory effect of Z-
vallesiachotamine was investigated. Just a few is known regarding
alkaloids effects on COMT; however, considering the COMT inhibi-
tion displayed by plant-derived C, it was  expected that Psychotria
MIA, as E/Z-vallesiachotamine, might also inhibit this enzyme.
When evaluating the compound in a range from 15 to 500 M,  it
was possible to determine an IC50 value of 196 M (92% maximum
inhibition). Compared to planar -carbolines, the lower activity
observed may  be due to the differentiated geometry given by the
monoterpenoid unit that is not present in P. harmala alkaloids. In
addition, the saturation of the N-containing ring affords ﬂexibility
to the ligand, and this feature can decrease the potency of THC
alkaloids as vallesiachotamine for COMT inhibition.
Passos et al. (2013b) evaluated E and Z-vallesiachotamine
regarding its monoamine oxidases (MAOs) and cholinesterases
(ChEs) inhibitory activities. The alkaloids were able to inhibit
butyrylcholinesterase (BChE) activity with IC50 of 7.08 and 9.77 M,
respectively. By docking studies, it was  observed that the indole
ring of E/Z-vallesiachotamine can establish hydrogen bonds with
Ser-198 and His-438 residues of BChE, while the residues Trp-82,
Trp-231, Leu-286, Phe-329, and Ile-442 can stabilize the compound
through van der Waals contacts with the carbon atoms of the ring
system. In addition, both compounds were able to inhibit MAO-
A activity, with IC50 of 2.14 and 0.85 M.  Molecular docking on
MAO-A revealed that the binding of E/Z-vallesiachotamine in MAO-
A is stabilized by hydrophobic interactions between the ligand and
the non-polar side chains of amino acids residues in the MAO-
A pocket. Polar contacts between the ligand and two conserved
water molecules, and Gln-215 side chain also contribute to the
complex stabilization. Finally, the carboxymethyl moieties of the
compounds are close to FAD cofactor, allowing a nucleophilic attack
by the N5 of FAD, creating a covalent bond and reinforcing the
irreversible binding.
Recently, the potential of E/Z-vallesiachotamine on sirtuins
(SIRT1 and SIRT2) modulation was also evaluated. SIRT are class
III histone deacetylases, responsible for the deacetylation of the
N-acetyl-lysine tails of histones and of non-histone substrates,
such as -tubulin. Sirtuin inhibition, especially SIRT2, has been
proposed as a new target to treat neurodegenerative diseases
(Dillin and Kelly, 2007; Maxwell et al., 2011; Donmez and Outeiro,
2013). The nonselective inhibition of SIRT1 and SIRT2 enzymes by
nicotinamide has shown to promote the restoration of cognitive
deﬁcits in a mice model of Alzheimer’s disease (Green et al., 2008).
By docking studies, Sacconnay et al. (2015) demonstrated that
the vallesiachotamine ring structure of E/Z-vallesiachotamine and
vallesiachotamine lactone is able to interact with Ala-262, Phe-273,
Phe-297, Ile-347, and Val-445 residues of SIRT1. In addition, the
acetyl group of these MIAs was able to make a hydrogen bond with
Ser-442 backbone. For SIRT2, Ala-85, Phe-96, Ile-69, Phe-119, and
Val-266 were involved in the stabilization of the complex between
protein and natural product. By in vitro assays, this nonselective
C. dos Santos Passos et al. / Revista Brasileira de Farmacognosia 25 (2015) 382–386 385
SAM SAM
BA
Asp-141 Asp-141
Asp-169 Asp-169
Asn-170 Asn-170
Pro-174 Pro-174
Leu-198 Leu-198
Trp-38 Trp-38
Arg-201 Arg-201
Cys-173 Cys-173
Met-40
Glu-199
Met-40
Glu-199
Mg2+ Mg2+
Fig. 1. Molecular docking results of Z-vallesiachotamine (A) and E-vallesiachotamine (B) in the cathecol-O-methyltransferase (COMT) catechol binding pocket (PDB ID: 3BWM;
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Ahe  carbon atoms of the protein are shown in gray, the carbon atoms of SAM are sh
btained for Z-vallesiachotamine (green) docking in COMT. (B) The best ranked solu
he  references to color in this ﬁgure legend, the reader is referred to the web versio
ffect of vallesiachotamine was conﬁrmed in a dose-dependent
ay.
Aiming at better understanding the interactions between Z-
allesiachotamine and COMT, molecular docking calculations were
erformed. As demonstrated in Fig. 1A, Z-vallesiachotamine was
ble to bind human COMT in the same pocket occupied by the
o-crystallized DNC. Nonpolar contacts, namely – stacking
nteractions with Trp-38, and van der Waals interactions with
et-40, Pro-174, and Leu-198, seem to stabilize the protein-
igand complex. On the contrary to what is observed for COMT
nhibitors containing cathecol groups, no coordination with the
g2+ ion was veriﬁed for Z-vallesiachotamine, which can explain
he IC50 value around 200 M.  In order to get additional clues
egarding to the binding mode of vallesiachotamine-like alkaloids
n COMT enzyme, the same docking protocol was  performed to
valuate the potential interactions between E-vallesiachotamine
nd COMT. E-vallesiachotamine was able to bind the DNC pocket
f human COMT, with the THC nucleus in the same orientation
bserved for its Z isomer. In addition to the nonpolar contacts with
rp-38, Met-40, Pro-174, and Leu-198, the aldehyde oxygen of E-
allesiachotamine can coordinate with Mg2+. This feature could
uggest that these two  structure-related MIA  might be able to
nhibit COMT showing different potencies and modes of inhibition.
Taking into account the obtained results, different MIA  may  be
valuated using the proposed screening assay in order to conﬁrm
r not their potential as COMT inhibitors, and to determine their
tructure–activity relationship. These secondary metabolites rep-
esent a source of chemical diversity and, based on this, they might
e used as scaffolds for the development of new chemical enti-
ies acting on targets related to neurodegeneration, and possessing
avorable pharmacokinetic and toxicological features.
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